Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Other hematologic neoplasm 1Myeloid 1

Conditions

Melanoma 3Skin Neoplasms 2Uveal Melanoma 1Eye Neoplasms 1

Interventions

Ipilimumab 101pembrolizumab 94Nivolumab 87Cyclophosphamide 69fludarabine phosphate 55aldesleukin 52Interleukin-2 39Dacarbazine 35Vemurafenib 31fludarabine 30trametinib 29dabrafenib 29Temozolomide 28Whole-Body Irradiation 21Aminolevulinic Acid 21Carboplatin 20CTLA-4 Antigen 20Bevacizumab 20Radiotherapy 19Peripheral Blood Stem Cell Transplantation 19Radiosurgery 18Tacrolimus 17Mycophenolic Acid 17Paclitaxel 16HhAntag691 163-ingenyl angelate 16Busulfan 15Introns 14Antilymphocyte Serum 14encorafenib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Peptides × Dermatologic × Clear all
NCT01970358 2025-12-29

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

Dana-Farber Cancer Institute

Phase 1 Completed
15 enrolled 8 charts
Dermatologic

Melanoma

NCT00254397 2019-10-16

Melanoma Vaccine With Peptides and Leuprolide

M.D. Anderson Cancer Center

Phase 2 Completed
98 enrolled 11 charts
Dermatologic

Uveal Melanoma, Eye Neoplasms, Melanoma, Skin Neoplasms

NCT00923195 2015-10-28

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
4 enrolled 11 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡